Filing Flows › Journey Medical (DERM) › Q3 2025
Journey Medical (DERM) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Journey Medical (DERM) reported revenue of $17.6M for the third quarter 2025 (Q3 2025), +21% from a year earlier and +17% from the quarter before. Operating margin was -8.7%, net loss $2.3M (13.1% of revenue).
Journey Medical, Q3 2025: revenue $17.6M (+20% year over year), operating margin -8.7%, net loss $2.3M, operating cash flow −$2.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.6M | +17% | +21% |
| Operating profit | −$1.5M | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | −$2.4M | — | — |
What changed
Revenue was $17.6M in Q3 2025, up 21% year over year and up 17% from the previous quarter. Qbrexza was the largest line at 42% of revenue. Foam franchise products (Amzeeq & Zilxi) declined 38%.
Operating costs exceeded revenue by $1.5M, an operating margin of -8.7%. Total costs grew 9% against revenue growth of 21%. The quarter ended with a net loss of $2.3M, narrower than the previous quarter's $3.8M loss.
Operating cash flow was −$2.4M. Non-cash charges added back $1.9M of share-based compensation. Working capital and other items used $1.9M.
Questions
What was Journey Medical's revenue in the third quarter 2025?
Journey Medical (DERM) reported revenue of $17.6M for the third quarter 2025 (Q3 2025), +21% from a year earlier and +17% from the quarter before.
Was Journey Medical profitable in the third quarter 2025?
Operating loss was $1.5M (-8.7% of revenue) and net loss $2.3M.
Source: Journey Medical 10-Q on SEC EDGAR.